Completed PHASE3 INTERVENTIONAL 1-arm NCT00163215

Growth Retardation In Children With Special Pathological Conditions Or Disease

Evolution Of Growth Rate In Children Suffering From A Disease Associated With Growth Retardation and Treated By Genotonorm. A Pilot Study.

Sponsor: Pfizer

Conditions Endocrine System Diseases

Interventions Somatropin

Updated 7 times since 2017 Last updated: Nov 19, 2012 Started: Jan 31, 2005 Primary completion: Oct 31, 2011 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Endocrine System Diseases and is currently completed. Pfizer leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Annemasse, France , Besançon, France , Bordeaux, France , Bron, France , Dijon, France , Grenoble, France , Lorient, France , Lyon, France , Marseille, France , Montpellier, France and 4 more locations